Lead
Who: The Advisory Committee on Immunization Practices (ACIP). When: A multi-day meeting that began Thursday, with a vote expected Friday. Where: Atlanta, Georgia; the process advises the U.S. Centers for Disease Control and Prevention (CDC). What: Members debated whether to alter the long-standing recommendation that all newborns receive hepatitis B vaccine within 24 hours of birth. Result: The vote was delayed once and previously postponed twice amid contentious debate and close review of proposed wording.
Key Takeaways
- Current CDC guidance recommends hepatitis B vaccination for all newborns within 24 hours of birth to prevent perinatal transmission and lifelong infection.
- About 1.4 billion people worldwide have received the hepatitis B vaccine over more than three decades of use.
- ACIP deferred a vote after heated discussion on Thursday and had postponed the decision twice before this meeting.
- The committee was reshaped this year after Robert F. Kennedy Jr., serving as health secretary, dismissed 17 prior advisers and appointed new members, including several vaccine skeptics.
- One proposal discussed would restrict or delay access to the birth dose—some advocates have suggested delaying the routine neonatal dose until 30 days in certain cases.
- There was no new peer-reviewed evidence presented at the meeting demonstrating harms from administering the birth dose within 24 hours.
- ACIP issues recommendations to the CDC director; the agency’s acting director, Jim O’Neill, will consider ACIP’s advice but is not required to adopt it verbatim.
- Institutional changes included a recent chair transition: Dr. Martin Kulldorff moved into an agency role and was replaced as committee chair by Dr. Kirk Milhoan.
Background
Hepatitis B is a viral infection that can cause severe liver disease and chronic infection when acquired at birth or in early childhood. To prevent mother-to-child transmission, U.S. policy for decades has recommended a birth dose of hepatitis B vaccine within 24 hours of delivery, a practice credited with sharply reducing perinatal infections.
The hepatitis B vaccine has been administered globally to roughly 1.4 billion people and is part of routine infant immunization schedules in many countries. ACIP, a federal advisory committee, evaluates vaccine safety, effectiveness and programmatic considerations and issues recommendations to the CDC, which then provides guidance to clinicians and public-health programs.
In 2025 the committee’s membership was overhauled after the health secretary replaced every member; that change and the appointment of several vaccine skeptics have intensified scrutiny of ACIP deliberations and raised questions about future U.S. vaccination policy.
Main Event
The ACIP meeting in Atlanta opened with sharp exchanges over proposed restrictions to the newborn hepatitis B shot. Some committee members and advisers argued for delaying routine neonatal dosing in favor of later administration in low-risk infants, while others emphasized the established benefits of the immediate birth dose.
Debate grew heated enough that the panel chose to postpone a planned Friday vote for additional review of the recommendation’s wording. This vote delay followed two earlier postponements earlier in the year, reflecting ongoing internal division and calls for more time to evaluate the implications.
Panel composition and leadership changes were a running theme of the meeting. Several recent appointees have previously expressed skepticism about established vaccine policies, and the committee’s most recent chair, Dr. Martin Kulldorff, transitioned to a different role within the agency and was succeeded by Dr. Kirk Milhoan, who has publicly criticized some COVID-19 vaccine policies.
Although participants raised safety concerns, reporters and attendees noted that no new empirical evidence linking the birth dose to specific harms was disclosed during the session. Instead, some members relied on limited studies or theoretical risk arguments when questioning the timing of the birth dose.
Analysis & Implications
A shift away from a universal birth dose could have significant public-health consequences. The first 24 hours are a critical window to prevent vertical transmission from mother to infant; delays increase the risk that perinatal infections will go unprotected, potentially raising childhood chronic hepatitis B rates over time.
Operationally, removing or narrowing the birth-dose recommendation would complicate hospital-based vaccine delivery systems that currently administer the shot before discharge. It could also widen disparities: infants whose families lack reliable follow-up care would be at disproportionate risk if vaccination were deferred to outpatient visits.
Politically, the fight spotlights how advisory panels are formed and how personnel changes at the top of health agencies can shift policy trajectories. ACIP’s role is advisory, but its guidance strongly influences insurer coverage, state vaccination programs and clinicians’ standard practices; therefore, any revision could ripple across health systems.
Internationally, a reversal or narrowing of the U.S. birth-dose policy could contrast with World Health Organization guidance and with routine practice in many countries, potentially undermining global harmonization of perinatal hepatitis B prevention strategies.
Comparison & Data
| Item | Current recommendation | Proposed/ discussed change |
|---|---|---|
| Timing | Within 24 hours of birth | Delay until 30 days or later in some proposals |
| Rationale | Prevent perinatal transmission | Concerns raised about risks and parental choice |
| Coverage (global) | ~1.4 billion doses administered historically | Not applicable — potential reduction in birth-dose uptake |
The table summarizes the status quo versus the types of changes discussed at ACIP. While the committee debated programmatic flexibility, the empirical evidence presented at the meeting did not document new safety harms tied to the birth dose. Operational and equity considerations were emphasized by several members as central to any policy change.
Reactions & Quotes
Two exchanges during the session underscored the evidentiary divide between members asking for data and advisers advocating for policy change based on limited or theoretical concerns.
“Is there any specific evidence of harm of giving this vaccination before 30 days? Or is this speculation?”
Joseph Hibbeln, ACIP member
Hibbeln’s question came during a back-and-forth with an adviser raising safety questions; it framed the meeting’s evidentiary debate and pointed to the limited empirical basis for altering the timing.
“There is limited evidence about the long-term risk,”
Mark Blaxill, senior CDC adviser
Blaxill, an author who has previously linked vaccines to developmental conditions, acknowledged the scarcity of long-term data as he defended proposals to reconsider timing. Observers noted that his recent appointment as a senior adviser at the CDC amplifies the impact of such perspectives on ACIP deliberations.
Unconfirmed
- Claims that giving the hepatitis B vaccine within 24 hours causes long-term developmental disorders remain unproven; the committee heard no new peer-reviewed evidence establishing such harms.
- Assertions that changing the recommendation would immediately lead to large-scale increases in hepatitis B incidence are projections; the exact magnitude would depend on implementation and follow-up coverage and is not yet quantifiable.
- Motivations attributed to specific individuals for reshaping ACIP (beyond documented personnel changes) are subject to interpretation and not independently verified in the meeting record.
Bottom Line
The ACIP vote — delayed but pending — could mark a pivotal moment for U.S. vaccination policy if the committee recommends narrowing or changing the universal birth-dose practice. Any such recommendation would be consequential for clinical practice, hospital operations and efforts to prevent perinatal hepatitis B transmission.
Because the meeting produced no new empirical proof of harm from the birth dose, public-health experts cautioned that policy changes should be grounded in robust evidence and accompanied by clear plans to preserve access and equity. Observers will watch the CDC director’s response should ACIP deliver a recommendation to modify the existing schedule.
Sources
- The Guardian (news report)
- Centers for Disease Control and Prevention — ACIP (U.S. federal advisory body information)
- Centers for Disease Control and Prevention — Hepatitis B vaccine information (official guidance and background)